myxothiazol and Leukemia--Myeloid--Acute

myxothiazol has been researched along with Leukemia--Myeloid--Acute* in 1 studies

Other Studies

1 other study(ies) available for myxothiazol and Leukemia--Myeloid--Acute

ArticleYear
Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.
    Blood, 2012, May-03, Volume: 119, Issue:18

    Chronic myeloid leukemia in chronic phase (CML-CP) is induced by BCR-ABL1 oncogenic tyrosine kinase. Tyrosine kinase inhibitors eliminate the bulk of CML-CP cells, but fail to eradicate leukemia stem cells (LSCs) and leukemia progenitor cells (LPCs) displaying innate and acquired resistance, respectively. These cells may accumulate genomic instability, leading to disease relapse and/or malignant progression to a fatal blast phase. In the present study, we show that Rac2 GTPase alters mitochondrial membrane potential and electron flow through the mitochondrial respiratory chain complex III (MRC-cIII), thereby generating high levels of reactive oxygen species (ROS) in CML-CP LSCs and primitive LPCs. MRC-cIII-generated ROS promote oxidative DNA damage to trigger genomic instability, resulting in an accumulation of chromosomal aberrations and tyrosine kinase inhibitor-resistant BCR-ABL1 mutants. JAK2(V617F) and FLT3(ITD)-positive polycythemia vera cells and acute myeloid leukemia cells also produce ROS via MRC-cIII. In the present study, inhibition of Rac2 by genetic deletion or a small-molecule inhibitor and down-regulation of mitochondrial ROS by disruption of MRC-cIII, expression of mitochondria-targeted catalase, or addition of ROS-scavenging mitochondria-targeted peptide aptamer reduced genomic instability. We postulate that the Rac2-MRC-cIII pathway triggers ROS-mediated genomic instability in LSCs and primitive LPCs, which could be targeted to prevent the relapse and malignant progression of CML.

    Topics: Animals; Catalase; Disease Progression; DNA Damage; DNA, Neoplasm; Electron Transport; Electron Transport Complex III; Fusion Proteins, bcr-abl; Genomic Instability; Humans; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic-Phase; Membrane Potential, Mitochondrial; Methacrylates; Mice; Neoplasm Proteins; Neoplastic Stem Cells; Polycythemia Vera; rac GTP-Binding Proteins; RAC2 GTP-Binding Protein; Reactive Oxygen Species; Recombinant Fusion Proteins; Superoxide Dismutase; Thiazoles

2012